Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
raltitrexed + oxaliplatin
- Development stage
- Phase 4
- Lead developer
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Raltitrexed + oxaliplatin (also known as the RALOX regimen) is a combination chemotherapy regimen being investigated for the treatment of advanced malignant biliary system tumors. Raltitrexed is a quinazoline folate analogue that functions as a potent and specific inhibitor of thymidylate synthase (TS), an enzyme essential for DNA synthesis. Oxaliplatin is a third-generation platinum-based antineoplastic agent that works by forming DNA adducts, which lead to intra-strand and inter-strand cross-links, effectively inhibiting DNA replication and transcription. This combination is primarily being studied as a second-line therapy in patients with unresectable advanced cholangiocarcinoma or gallbladder carcinoma who have failed first-line treatments.
- Other names
- raltitrexed + oxaplatin
02
Targets
DNATS (Thymidylate synthase)
Beyond the preview
Go deeper on raltitrexed + oxaliplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on raltitrexed + oxaliplatin.